This inventor holds 2 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Sitari Pharma, Inc.. Active years: 2023-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2024
Title: Thomas R. Diraimondo: Innovator in Transglutaminase Inhibition
Introduction
Thomas R. Diraimondo is a notable inventor based in La Jolla, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of transglutaminase 2 (TG2) inhibitors. With a total of 2 patents, his work is paving the way for new treatments in various medical conditions.
Latest Patents
Diraimondo's latest patents focus on compounds and pharmaceutical compositions that inhibit transglutaminase 2 (TG2). These patents describe methods for using TG2 inhibitors, either alone or in combination with other compounds, to treat diseases or conditions that would benefit from TG2 inhibition. His innovative approach has the potential to impact numerous therapeutic areas.
Career Highlights
Currently, Thomas R. Diraimondo is associated with Sitari Pharma, Inc., where he continues to advance his research and development efforts. His expertise in the field has positioned him as a key player in the pharmaceutical industry.
Collaborations
Diraimondo collaborates with talented individuals such as David Campbell and Justin Chapman, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Thomas R. Diraimondo's work in developing TG2 inhibitors showcases his commitment to advancing medical science. His contributions are significant in the quest for effective treatments, and his ongoing research promises to yield further advancements in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile